{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Alzamend Neuro Announces Reverse Stock Split - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"YwbMmERdYv\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/\">Alzamend Neuro Announces Reverse Stock Split<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-announces-reverse-stock-split\/embed\/#?secret=YwbMmERdYv\" width=\"600\" height=\"338\" title=\"&#8220;Alzamend Neuro Announces Reverse Stock Split&#8221; &#8212; Market Newsdesk\" data-secret=\"YwbMmERdYv\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) &#8212; Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder (\u201cBD\u201d), major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that Alzamend\u2019s board of directors approved a one-for-nine reverse stock split of Alzamend\u2019s common stock (\u201cCommon Stock\u201d) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company\u2019s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company\u2019s existing trading symbol \u201cALZN\u201d. The new CUSIP number for the Common &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NzI1OSM2OTI5MDcwIzUwMDEzMzAzMQ=="}